Moringa oleifera as an Anti-Cancer Agent against Breast and Colorectal Cancer Cell Lines.
In this study we investigated the anti-cancer effect of Moringa oleifera leaves, bark and seed extracts. When tested against MDA-MB-231 and HCT-8 cancer cell lines, the extracts of leaves and bark showed remarkable anti-cancer properties while surprisingly, seed extracts exhibited hardly any such properties. Cell survival was significantly low in both cells lines when treated with leaves and bark extracts. Furthermore, a striking reduction (about 70-90%) in colony formation as well as cell motility was observed upon treatment with leaves and bark. Additionally, apoptosis assay performed on these treated breast and colorectal cancer lines showed a remarkable increase in the number of apoptotic cells; with a 7 fold increase in MD-MB-231 to an increase of several fold in colorectal cancer cell lines. However, no significant apoptotic cells were detected upon seeds extract treatment. Moreover, the cell cycle distribution showed a G2/M enrichment (about 2-3 fold) indicating that these extracts effectively arrest the cell progression at the G2/M phase. The GC-MS analyses of these extracts revealed numerous known anti-cancer compounds, namely eugenol, isopropyl isothiocynate, D-allose, and hexadeconoic acid ethyl ester, all of which possess long chain hydrocarbons, sugar moiety and an aromatic ring. This suggests that the anti-cancer properties of Moringa oleifera could be attributed to the bioactive compounds present in the extracts from this plant. This is a novel study because no report has yet been cited on the effectiveness of Moringa extracts obtained in the locally grown environment as an anti-cancer agent against breast and colorectal cancers. Our study is the first of its kind to evaluate the anti-malignant properties of Moringa not only in leaves but also in bark. These findings suggest that both the leaf and bark extracts of Moringa collected from the Saudi Arabian region possess anti-cancer activity that can be used to develop new drugs for treatment of breast and colorectal cancers.
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Abdulrahman Khazim
AK
Al-Asmari
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Sulaiman Mansour
SM
Albalawi
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Md Tanwir
MT
Athar
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Abdul Quaiyoom
AQ
Khan
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Hamoud
H
Al-Shahrani
Research Center, Prince Sultan Military Medical City, Riyadh, 11159, Kingdom of Saudi Arabia.
Mozaffarul
M
Islam
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D059565:G2 Phase Cell Cycle Checkpoints / Q000187:drug effects; D006801:Humans; D029588:Moringa oleifera / Q000378:metabolism*; D024301:Plant Bark / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology*; D018515:Plant Leaves / Q000378:metabolism; D012529:Saudi Arabia; D012639:Seeds / Q000378:metabolism
D000970:Antineoplastic Agents; D010936:Plant Extracts